journal article·2019-10-25

Nanocellulose-Based Nanoporous Filter Paper for Virus Removal Filtration of Human Intravenous Immunoglobulin

Lulu Wu, Levon Manukyan, Athanasios Mantas, Albert Mihranyan

ACS Applied Nano Materials· Volume 2· Issue 10
Publisher page

Abstract

Human intravenous immunoglobulin (IVIG) is a highly valuable plasma-derived biotherapeutic with several important clinical indications in primary and acquired immunodeficiencies as well as autoimmune diseases, especially neuropathies. Ensuring the viral safety of plasma-derived products, such as human IVIG, is mandatory. Viral filtration is commonly used to affect viral removal in the manufacture of plasma products. Viral filtration of large volumes of a IVIG feed solution can take significant time, the required filter area can be large, and the resultant total cost of filtration is considerable. Therefore, there is a need for a high-capacity filter, which can process large volumes of plasma-derived biotherapeutic products within a short time at reduced cost. Here, we describe for the first time the performance of a nanocellulose-based virus removal filter paper in the processing of human IVIG, which has the potential to address the above-stated issues. The filter exhibited 5–6 log virus clearance of ΦX174 (28 nm; pI 6.6) or MS2 (27 nm; pI 3.9) phages during the filtration of spiked IVIG solutions (11 mg/mL, pH 4.9). To simulate real-life production conditions, filtration at 288 L/m2, corresponding to 3 kg of protein/m2, at 3 bar was undertaken. No substantial filter fouling was evident, with the flux remaining stable throughout filtration at 20–30 L/m2·h. The predicted volumetric capacity Vmax was ≥1700 L/m2, which corresponds to the processing of ≥19 kg/m2 of immunoglobulins. A number of characterization tests encompassing size-exclusion high-pressure liquid chromatography, dynamic light scattering, and polyacrylamide gel electrophoresis confirmed immunoglobulin integrity before and after filtration. This study has shown that a mille-feuille filter paper manufacturing process offers the possibility of producing cost-efficient viral removal filters with the required performance capabilities suitable for the processing of plasma-derived immunoglobulins and recombinant monoclonal antibodies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunodeficiency and Autoimmune Disorders · Parvovirus B19 Infection Studies · Platelet Disorders and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Nanotechnology and Functional Materials, Department of Engineering Sciences, Uppsala University, Box 534, 751 21 Uppsala, Sweden

Funding

Vetenskapsr?det · Knut och Alice Wallenbergs Stiftelse · H2020 European Institute of Innovation and Technology · Chinese Academy of Sciences

References (34)

Show source-provided references
1. 10.1016/j.tips.2004.04.00210.1016/j.tips.2004.04.002 ↗
2. 10.4049/jimmunol.170127110.4049/jimmunol.1701271 ↗
3. Agency, E. M. Guideline core SmPc human normal immunoglobulin intravenous administration IvIg.EMA/CHMP/BPWP/94038/2007, revision 5; 2018.
4. 10.3389/fimmu.2014.0066510.3389/fimmu.2014.00665 ↗
5. 10.2146/ajhp05028210.2146/ajhp050282 ↗
6. 10.2146/ajhp07058210.2146/ajhp070582 ↗
7. 10.1038/nri340110.1038/nri3401 ↗
8. 10.1385/CRIAI:29:3:33310.1385/CRIAI:29:3:333 ↗
9. 10.1331/10865800276331688810.1331/108658002763316888 ↗
10. WHO Expert Committee on Biological Standardization; World Health Organisation: Geneva, Switzerland, 2004.
11. 10.1002/biot.20050003710.1002/biot.200500037 ↗
12. Buchacher A. · 2013 · 18510.1002/9781118356807.ch13 ↗
13. Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.CPMP/ICH/295/95; European Medicines Agency, 1995.
14. Technical Report No. 41: Virus Filtration; PDA, 2005; pp 1–42.10.1016/S0015-1882(05)70732-1 ↗
15. 10.1002/jps.2388110.1002/jps.23881 ↗
16. 10.1016/j.memsci.2005.10.05710.1016/j.memsci.2005.10.057 ↗
17. 10.1016/j.biologicals.2010.02.00810.1016/j.biologicals.2010.02.008 ↗
18. 10.1007/s40259-017-0212-y10.1007/s40259-017-0212-y ↗
19. 10.1016/j.biologicals.2017.10.00610.1016/j.biologicals.2017.10.006 ↗
20. 10.1016/j.biologicals.2018.01.00410.1016/j.biologicals.2018.01.004 ↗
21. 10.1016/j.biologicals.2014.11.00510.1016/j.biologicals.2014.11.005 ↗
22. Bolton G. · BioPharm. International · 2004 · 17 · 38
23. 10.1002/adhm.20130064110.1002/adhm.201300641 ↗
24. 10.1039/C6MH00090H10.1039/C6MH00090H ↗
25. 10.1021/acsami.6b0309310.1021/acsami.6b03093 ↗
26. 10.1016/j.memsci.2018.11.00210.1016/j.memsci.2018.11.002 ↗
27. 10.1016/j.biologicals.2015.08.00110.1016/j.biologicals.2015.08.001 ↗
28. 10.1002/gch2.20180003110.1002/gch2.201800031 ↗
29. 10.1021/acs.langmuir.7b0056610.1021/acs.langmuir.7b00566 ↗
30. Badmington F. · Pharm. Technol. · 1995 · 19 · 64
31. 10.1016/j.tca.2005.02.01510.1016/j.tca.2005.02.015 ↗
32. Dedeo M. T. · 2011 · 103 · 353
33. 10.1111/j.1365-2672.2010.04663.x10.1111/j.1365-2672.2010.04663.x ↗
34. 10.1111/j.1423-0410.2009.01226.x10.1111/j.1423-0410.2009.01226.x ↗